

## **Bio-Works Technologies publishes prospectus relating to the fully secured rights issue**

**THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.**

**Bio-Works Technologies AB ("Bio-Works" or the "Company") publishes today, on August 6, 2024, a prospectus relating to the Company's fully secured rights issue of approximately SEK 39 million before issue costs, whose subscription period begins on August 13, 2024. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and will be available on the Swedish Financial Supervisory Authority's ([www.fi.se](http://www.fi.se)) website. The prospectus is also available on the Company's ([www.bio-works.com](http://www.bio-works.com)), Sedermera Corporate Finance AB's ([www.sedermera.se](http://www.sedermera.se)) and Nordic Issuing AB's ([www.nordic-issuing.se](http://www.nordic-issuing.se)) respective websites.**

### **Publication of prospectus**

On June 26, 2024, Bio-Works announced that the Board of Directors had decided on a fully secured rights issue of approximately SEK 39 million before issue costs. On July 29, 2024, the Extraordinary General Meeting approved the Board's decision on the rights issue.

The prospectus, containing complete terms and conditions, has today, on August 6, 2024, been approved and registered by the Swedish Financial Supervisory Authority and will be published on the Swedish Financial Supervisory Authority's website ([www.fi.se](http://www.fi.se)). The prospectus is also available on the Company's ([www.bio-works.com](http://www.bio-works.com)), Sedermera Corporate Finance AB's ([www.sedermera.se](http://www.sedermera.se)) and Nordic Issuing AB's ([www.nordic-issuing.se](http://www.nordic-issuing.se)) respective websites. The prospectus has only been drafted in Swedish.

A summary information folder (in Swedish and English) will be published on the Company's, Sedermera Corporate Finance AB's and Nordic Issuing AB's respective websites in connection with the start of the subscription period.

### **Indicative timetable for the rights issue**

|   |                   |
|---|-------------------|
| Last day of trading in the share including the right to receive unit rights:  | August 7 2024     |
| First day of trading in the share excluding the right to receive unit rights: | August 8 2024     |
| Record date for participation in the rights issue:                            | August 9 2024     |
| Subscription period:  | August 13-27 2024 |
| Trading in unit rights:   | August 13-22 2024 |
| Announcement of final outcome of the rights issue:                            | August 28 2024    |

Trading in paid subscribed Units (BTU) is expected to take place from August 13, 2024, until the Swedish Companies Registration Office has registered the rights issue. The last day of trading in BTUs will be announced through a separate press release after the completion of the rights issue.

### Advisors

In connection with the rights issue, Sedermera Corporate Finance AB is the financial advisor ([www.sedermera.se](http://www.sedermera.se)), Markets & Corporate Law Nordic AB is the legal advisor ([www.mcl.law](http://www.mcl.law)) and Nordic Issuing AB acts as the issuing agent ([www.nordic-issuing.se](http://www.nordic-issuing.se)).

### Contact details

For more information about the Company, please visit Bio-Works' website, [www.bio-works.com](http://www.bio-works.com), or contact Arne Hauge, CFO, e-mail: [arne.hauge@bio-works.com](mailto:arne.hauge@bio-works.com), telephone: +46 (0) 8 - 502 705.

For further information about the rights issue, please contact:

Sedermera Corporate Finance AB  
Telephone: +46 40 615 14 10  
E-mail: [cf@sedermera.se](mailto:cf@sedermera.se)  
Website: [www.sedermera.se](http://www.sedermera.se)

### About Bio-Works

Bio-Works helps the Biotechnology industry to achieve its goals for the purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for Bioprocessing. Our vision is to be a trusted and dynamic partner for a growing and evolving industry.

Bio-Works headquarters, with R&D and manufacturing, is located in Uppsala Business Park, Uppsala, Sweden. We supply our products to a global market, through a combination of direct sales and distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For further information please contact us, [www.bio-works.com](http://www.bio-works.com).

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

**IMPORTANT INFORMATION**

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Bio-Works in any jurisdiction, neither from Bio-Works nor from someone else.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus, corresponding to an EU Growth Prospectus regarding the Rights Issue described in this press release will be prepared and published by the Company on the Company's web page after the prospectus has been scrutinized and approved by the Swedish Financial Supervisory Authority ("SFSA") (Sw. Finansinspektionen). The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Sedermera is acting for Bio-Works in connection with the Rights Issue and no one else and will not be responsible to anyone other than Bio-Works for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus, or any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

### **Forward-Looking Statements**

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law, or Spotlight Stock Market rule book or for the Company applicable rule book for issuers.

### **DISCLOSURE TO INVESTORS PURSUANT TO THE ACT (2023:560) ON THE SCREENING OF FOREIGN DIRECT INVESTMENTS**

The Act (2023:560) on the Screening of Foreign Direct Investments ("FDI Act") applies to the company's operations. In the event that the subscription of new units or subscription of shares under warrants would result in an investor, after the investment, directly or indirectly, holding votes representing or exceeding any of the thresholds of 10, 20, 30, 50, 65, or 90 percent of the votes in the company, the investor is required to notify their investment to the Inspectorate for Strategic Products in accordance with the FDI Act.

### **INFORMATION TO DISTRIBUTORS**

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Bio-Works have been subject to a product

approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment").

Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Bio-Works may decline and investors could lose all or part of their investment; the shares in Bio-works offer no guaranteed income and no capital protection; and an investment in the shares in Bio-works is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Bio-Works.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Bio-Works and determining appropriate distribution channels.

**Attachments**

[Bio-Works Technologies publishes prospectus relating to the fully secured rights issue](#)